Global Hypercholesterolemia Treatment Market 2018 by Manufacturers, Countries, Type and Application, Forecast to 2023
- SKU ID : GIR-GIR1809200199 13134785
- |
- Publishing Date: 15-Nov-2018
- |
- Region: Global
- |
- No. of pages: 118
Hypercholesterolemia is a genetic disorder characterized by very high levels of cholesterol in the blood. Hypercholesterolemia, also termed as dyslipidemia, is a form of hyperlipidemia and hyperlipoproteinemia in the body. Presence of low-density Lipoprotein Cholesterol (LDL-C) or bad cholesterol in the blood, may lead to cardiovascular diseases. Hypercholesterolemia is caused due to a combination of genetic and environmental factors. Environmental factors include excessive diet intake and obesity. In case of genetic factors, the number of copies of the gene determines the severity of the disease. People with the homozygous form (two copies of the gene) generally suffer from severe cardiovascular diseases during childhood, while those with the heterozygous form (with a single copy of the gene) suffer from heart diseases in their 30s or 40s.
Scope of the Report:
The global Hypercholesterolemia Treatment market is valued at xx million USD in 2017 and is expected to reach xx million USD by the end of 2023, growing at a CAGR of xx% between 2017 and 2023.
The Asia-Pacific will occupy for more market share in following years, especially in China, also fast growing India and Southeast Asia regions.
North America, especially The United States, will still play an important role which cannot be ignored. Any changes from United States might affect the development trend of Hypercholesterolemia Treatment.
Europe also play important roles in global market, with market size of xx million USD in 2017 and will be xx million USD in 2023, with a CAGR of xx%.
This report studies the Hypercholesterolemia Treatment market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the Hypercholesterolemia Treatment market by product type and applications/end industries.
Market Segment by Companies, this report covers
CymaBay Therapeutics Inc
Daewoong Co Ltd
Gemphire Therapeutics Inc
LipimetiX Development Inc
Regeneron Pharmaceuticals Inc
RegenxBio Inc
The Medicines Company
Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
AEM-2802
AEM-2814
Alirocumab
Evinacumab
Others
Market Segment by Applications, can be divided into
Clinic
Hospital
Others
Scope of the Report:
The global Hypercholesterolemia Treatment market is valued at xx million USD in 2017 and is expected to reach xx million USD by the end of 2023, growing at a CAGR of xx% between 2017 and 2023.
The Asia-Pacific will occupy for more market share in following years, especially in China, also fast growing India and Southeast Asia regions.
North America, especially The United States, will still play an important role which cannot be ignored. Any changes from United States might affect the development trend of Hypercholesterolemia Treatment.
Europe also play important roles in global market, with market size of xx million USD in 2017 and will be xx million USD in 2023, with a CAGR of xx%.
This report studies the Hypercholesterolemia Treatment market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the Hypercholesterolemia Treatment market by product type and applications/end industries.
Market Segment by Companies, this report covers
CymaBay Therapeutics Inc
Daewoong Co Ltd
Gemphire Therapeutics Inc
LipimetiX Development Inc
Regeneron Pharmaceuticals Inc
RegenxBio Inc
The Medicines Company
Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
AEM-2802
AEM-2814
Alirocumab
Evinacumab
Others
Market Segment by Applications, can be divided into
Clinic
Hospital
Others
Frequently Asked Questions
This market study covers the global and regional market with an in-depth analysis of the overall growth prospects in the market. Furthermore, it sheds light on the comprehensive competitive landscape of the global market. The report further offers a dashboard overview of leading companies encompassing their successful marketing strategies, market contribution, recent developments in both historic and present contexts.
- By product type
- By End User/Applications
- By Technology
- By Region
The report provides a detailed evaluation of the market by highlighting information on different aspects which include drivers, restraints, opportunities, and threats. This information can help stakeholders to make appropriate decisions before investing.
Please Select a Format
